Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells

Immunological Reviews

Volumn 250, Issue 1, 2012, Pages 167-179

  Girardi, Enrico ^a   Zajonc, Dirk M ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Antigen presentation; CD1d; Lipids; Natural killer T cell; T cell receptor

Indexed keywords

CD1D ANTIGEN; CD3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCEROLIPID; INTERLEUKIN 12; INTERLEUKIN 18; SPHINGOLIPID; SULFATIDE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; ENDOPLASMIC RETICULUM; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; ANTIGENS, CD1D; BINDING SITES; EPITOPES; HUMANS; KILLER CELLS, NATURAL; LIPIDS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, ANTIGEN, T-CELL;

EID: 84867410787     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01166.x     Document Type: Article

References (154)

1. Porcelli S, Brenner MB, Greenstein JL, Terhorst C, Balk SP, Bleicher PA. Recognition of cluster of differentiation 1 antigens by human CD4-CD8- cytolytic T lymphocytes. Nature 1989;184:3306-3309.
2. + T lymphocytes. Science 1995;268:863-865.
3. Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature 1992;360:593-597.
4. Dascher CC. Evolutionary biology of CD1. Curr Top Microbiol Immunol 2007;314:3-26.
5. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890.
6. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900.
7. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-336.
8. Balk SP, et al. Beta 2-microglobulin-independent MHC class Ib molecule expressed by human intestinal epithelium. Science 1994;265:259-262.
9. Sugita M, et al. Separate pathways for antigen presentation by CD1 molecules. Immunity 1999;11:743-752.
10. Hava DL, et al. CD1 assembly and the formation of CD1-antigen complexes. Curr Opin Immunol 2005;17:88-94.
11. Zeng Z, Castaño AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997;277:339-345.
12. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 2005;5:387-399.
13. Zajonc DM, Wilson IA. Architecture of CD1 proteins. Curr Top Microbiol Immunol 2007;314:27-50.
14. Calabi F, Milstein C. A novel family of human major histocompatibility complex-related genes not mapping to chromosome 6. Nature 1986;323:540-543.
15. Calabi F, Jarvis J, Martin L. Two classes of CD1 genes. Eur J Immunol 1989;19:285-292.
16. de la Salle H, et al. Assistance of microbial glycolipid antigen processing by CD1e. Science 2005;310:1321-1324.
17. Zajonc DM, Striegl H, Dascher CC, Wilson IA. The crystal structure of avian CD1 reveals a smaller, more primordial antigen-binding pocket compared to mammalian CD1. Proc Natl Acad Sci USA 2008;105:17925-17930.
18. Dvir H, Wang J, Ly N, Dascher CC, Zajonc DM. Structural basis for lipid-antigen recognition in avian immunity. J Immunol 2010;184:2504-2511.
19. Looringh van Beeck FA, et al. Two canine CD1a proteins are differentially expressed in skin. Immunogenetics 2008;60:315-324.
20. Van Rhijn I, et al. The bovine CD1 family contains group 1 CD1 proteins, but no functional CD1d. J Immunol 2006;176:4888-4893.
21. Zajonc DM, Elsliger MA, Teyton L, Wilson IA. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol 2003;4:808-815.
22. Zajonc DM, et al. Molecular mechanism of lipopeptide presentation by CD1a. Immunity 2005;22:209-219.
23. Gadola SD, et al. Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains. Nat Immunol 2002;3:721-726.
24. Batuwangala T, et al. The crystal structure of human CD1b with a bound bacterial glycolipid. J Immunol 2004;172:2382-2388.
25. Garcia-Alles LF, et al. Endogenous phosphatidylcholine and a long spacer ligand stabilize the lipid-binding groove of CD1b. EMBO J 2006;25:3684-3692.
26. Scharf L, et al. The 2.5 Å structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 2010;33:853-862.
27. Garcia-Alles LF, et al. Crystal structure of human CD1e reveals a groove suited for lipid-exchange processes. Proc Natl Acad Sci USA 2011;108:13230-13235.
28. Bradbury A, Belt K, Neri T, Milstein C. Mouse CD1 is distinct from and co-exists with TL in the same thymus. EMBO J 1988;7:3081-3086.
29. Chen Y, Wang B, Chun T, Zhao L. Expression of CD1d2 on thymocytes is not sufficient for the development of NK T cells in CD1d1-deficient mice. J Immunol 1999;162:4560-4566.
30. Koch M, et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005;6:819-826.
31. Zajonc DM, et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005;6:810-818.
32. Joyce S, Girardi E, Zajonc DM. NKT cell ligand recognition logic: molecular basis for a synaptic duet and transmission of inflammatory effectors. J Immunol 2011;187:1081-1089.
33. De Libero G, Mori L. Mechanisms of lipid-antigen generation and presentation to T cells. Trends Immunol 2006;27:485-492.
34. De Libero G, Mori L. Novel insights into lipid antigen presentation. Trends Immunol 2012;33:103-111.
35. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol 2007;7:929-941.
36. van den Elzen P, et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005;437:906-910.
37. Freigang S, et al. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. J Clin Invest 2010;120:1873-1884.
38. Roy KC, Maricic I, Khurana A, Smith TRF, Halder RC, Kumar V. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol 2008;180:2942-2950.
39. Zhou D, et al. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 2004;303:523-527.
40. Yuan W, et al. Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc Natl Acad Sci USA 2007;104:5551-5556.
41. Winau F, et al. Saposin C is required for lipid presentation by human CD1b. Nat Immunol 2004;5:169-174.
42. León L, et al. Saposins utilize two strategies for lipid transfer and CD1 antigen presentation. Proc Natl Acad Sci USA 2012;109:4357-4364.
43. Dougan SK, et al. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med 2005;202:529-539.
44. Prigozy TI, et al. Glycolipid antigen processing for presentation by CD1d molecules. Science 2001;291:664-667.
45. Yuan W, Kang S-J, Evans JE, Cresswell P. Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. J Immunol 2009;182:4784-4791.
46. Cox D, et al. Determination of cellular lipids bound to human CD1d molecules. PLoS ONE 2009;4:e5325.
47. Haig NA, Guan Z, Li D, McMichael A, Raetz CRH, Xu X-N. Identification of self-lipids presented by CD1c and CD1d. J Biol Chem 2011;286:37692-37701.
48. Kinjo Y, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-525.
49. Mattner J, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-529.
50. Kinjo Y, et al. Natural Sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells. Chem Biol 2008;15:654-664.
51. Kinjo Y, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006;7:978-986.
52. Kinjo Y, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol 2011;12:966-974.
53. Chang Y-J, et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest 2011;121:57-69.
54. Castaño AR, et al. Peptide binding and presentation by mouse CD1. Science 1995;269:223-226.
55. Tangri S, Brossay L, Burdin N, Lee DJ, Corr M, Kronenberg M. Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing. Proc Natl Acad Sci USA 1998;95:14314-14319.
56. Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Invest 2011;121:249-264.
57. Van Rhijn I, et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci USA 2004;101:13578-13583.
58. Kawano T, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
59. Sullivan BA, et al. Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol 2010;184:141-153.
60. Schiefner A, Fujio M, Wu D, Wong C-H, Wilson IA. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands. J Mol Biol 2009;394:71-82.
61. Tyznik AJ, et al. Glycolipids that elicit IFN-γ-biased responses from natural killer T cells. Chem Biol 2011;18:1620-1630.
62. Wu D, et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc Natl Acad Sci USA 2006;103:3972-3977.
63. Zajonc DM, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 2005;202:1517-1526.
64. Wang J, et al. Lipid binding orientation within CD1d affects recognition of Borrelia burgorferi antigens by NKT cells. Proc Natl Acad Sci USA 2010;107:1535-1540.
65. Rauch J, et al. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem 2003;278:47508-47515.
66. Dieudé M, et al. Cardiolipin binds to CD1d and stimulates CD1d-restricted γδ T cells in the normal murine repertoire. J Immunol 2011;186:4771-4781.
67. Brossay L, Naidenko O, Burdin N, Matsuda J, Sakai T, Kronenberg M. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J Immunol 1998;161:5124-5128.
68. Kamada N, et al. Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to V(alpha)14 NKT cells. Int Immunol 2001;13:853-861.
69. Zajonc DM, Ainge GD, Painter GF, Severn WB, Wilson IA. Structural characterization of mycobacterial phosphatidylinositol mannoside binding to mouse CD1d. J Immunol 2006;177:4577-4583.
70. Zajonc DM, Savage PB, Bendelac A, Wilson IA, Teyton L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J Mol Biol 2008;377:1104-1116.
71. Mallevaey T, et al. A molecular basis for NKT cell recognition of CD1d-self-antigen. Immunity 2011;34:315-326.
72. Agea E, et al. Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med 2005;202:295-308.
73. Russano AM, et al. Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted gamma delta T cells. J Allergy Clin Immunol 2006;117:1178-1184.
74. Russano AM, et al. CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. J Immunol 2007;178:3620-3626.
75. Godfrey DI, Macdonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-237.
76. Wei DG, Curran SA, Savage PB, Teyton L, Bendelac A. Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells and consequences for microbial glycolipid recognition. J Exp Med 2006;203:1197-1207.
77. Gapin L. iNKT cell autoreactivity: what is "self" and how is it recognized? Nat Rev Immunol 2010;10:272-277.
78. + T cells in major histocompatibility complex class II-deficient mice. J Exp Med 1995;182:993-1004.
79. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001;193:893-904.
80. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci USA 2010;107:10984-10989.
81. Exley MA, et al. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001;167:5531-5534.
82. Exley MA, et al. Cutting edge: compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol 2002;168:1519-1523.
83. Durante-Mangoni E, et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol 2004;173:2159-2166.
84. Fuss IJ, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-1497.
85. Engel I, et al. Co-receptor choice by V alpha14i NKT cells is driven by Th-POK expression rather than avoidance of CD8-mediated negative selection. J Exp Med 2010;207:1015-1029.
86. Sidobre S, Kronenberg M. CD1 tetramers: a powerful tool for the analysis of glycolipid-reactive T cells. J Immunol Methods 2002;268:107-121.
87. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004;199:947-957.
88. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007;117:2302-2312.
89. Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 2011;140:646-655.
90. Yang SH, et al. Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury. J Am Soc Nephrol 2011;22:1305-1314.
91. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001;194:313-320.
92. + type II NKT cells mediate ICOS and programmed death-1-dependent regulation of Type 1 diabetes. J Immunol 2012;188:3138-3149.
93. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-594.
94. Terabe M, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-1633.
95. Ambrosino E, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-5136.
96. Ambrosino E, Berzofsky JA, Terabe M. Regulation of tumor immunity: the role of NKT cells. Expert Opin Biol Ther 2008;8:725-734.
97. Gadola SD, et al. Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors. J Exp Med 2006;203:699-710.
98. Kjer-Nielsen L, et al. A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. J Exp Med 2006;203:661-673.
99. Scott-Browne JP, et al. Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat Immunol 2007;8:1105-1113.
100. Florence WC, et al. Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands. EMBO J 2009;28:3579-3590.
101. Borg NA, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007;448:44-49.
102. Pellicci DG, et al. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 2009;31:47-59.
103. Patel O, et al. Vβ2 natural killer T cell antigen receptor-mediated recognition of CD1d-glycolipid antigen. Proc Natl Acad Sci USA 2011;108:19007-19012.
104. Li Y, et al. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. J Exp Med 2010;207:2383-2393.
105. Aspeslagh S, et al. Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J 2011;30:8413-8421.
106. Pellicci DG, et al. Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol 2011;12:827-834.
107. Girardi E, et al. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells. PLoS Biol 2011;9:e1001189.
108. Yu ED, Girardi E, Wang J, Zajonc DM. Cutting edge: structural basis for the recognition of β-linked glycolipid antigens by invariant NKT cells. J Immunol 2011;187:2079-2083.
109. Patel O, et al. NKT TCR recognition of CD1d-α-C-galactosylceramide. J Immunol 2011;187:827-833.
110. Kerzerho J, et al. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties. J Immunol 2012;188:2254-2265.
111. López-Sagaseta J, Sibener LV, Kung JE, Gumperz J, Adams EJ. Lysophospholipid presentation by CD1d and recognition by a human natural killer T-cell receptor. EMBO J 2012;24:1-13.
112. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006;24:419-466.
113. Brossay L, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-1528.
114. Sidobre S, et al. The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc Natl Acad Sci USA 2004;101:12254-12259.
115. Wun KS, et al. A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity 2011;34:327-339.
116. Tynan FE, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 2007;8:268-276.
117. Zhou D, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-1789.
118. Bozna BL, et al. Binding strength and dynamics of invariant natural killer cell T cell receptor/CD1d-glycosphingolipid interaction on living cells by single molecule force spectroscopy. J Biol Chem 2011;286:15973-15979.
119. Sidobre S, Naidenko OV, Sim B-C, Gascoigne NRJ, Garcia KC, Kronenberg M. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J Immunol 2002;169:1340-1348.
120. Stanic A, et al. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural TCR. J Immunol 2003;171:4539-4551.
121. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 2002;418:552-556.
122. Matsuda JL, Gapin L, Fazilleau N, Warren K, Naidenko OV, Kronenberg M. Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor beta repertoire and small clone size. Proc Natl Acad Sci USA 2001;98:12636-12641.
123. Gui M, Li J, Wen L-J, Hardy RR, Hayakawa K. TCR beta chain influences but does not solely control autoreactivity of Valpha14J281T cells. J Immunol 2001;167:6239-6246.
124. + NK T cells. J Immunol 2001;166:1755-1762.
125. + CD4-CD8- T cells. J Exp Med 1997;186:109-120.
126. Porcelli S, Yockey C, Brenner M, Balk S. Antigen receptor (TCR) expression by human peripheral blood CD4-8-cr T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 1993;178:1-16.
127. Matulis G, et al. Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop. PLoS Biol 2010;8:e1000402.
128. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000;191:1895-1903.
129. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529-534.
130. Yamaguchi Y, et al. Enhancing effects of (2S, 3S, 4R)-1-O-(alpha-d-galactopyranosyl)-2-(N-hexacosanoylamino) -1, 3, 4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol Res 1996;8:399-407.
131. + NK T lymphocytes. J Immunol 1998;161:3271-3281.
132. Hayakawa Y, et al. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 2001;31:1720-1727.
133. + T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002;99:1259-1266.
134. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999;163:2387-2391.
135. Cui J, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-1626.
136. Baxevanis CN, Gritzapis AD, Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol 2003;171:2953-2959.
137. Parekh VV, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005;115:2572-2583.
138. Tahir SM, et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-4050.
139. Dhodapkar MV, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003;197:1667-1676.
140. Giaccone G, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-3709.
141. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001;413:531-534.
142. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003;198:1631-1641.
143. Im JS, et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 2009;30:888-898.
144. Bai L, et al. Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer. Proc Natl Acad Sci USA 2009;106:10254-10259.
145. Bai L, et al. Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo. J Immunol 2012;188:3053-3061.
146. Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol 2010;22:68-78.
147. Silk JD, et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 2008;180:6452-6456.
148. Cerundolo V, Barral P, Batista FD. Synthetic iNKT cell-agonists as vaccine adjuvants-finding the balance. Curr Opin Immunol 2010;22:417-424.
149. Li X, et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA 2010;107:13010-13015.
150. Padte NN, Li X, Tsuji M, Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 2011;140:142-151.
151. Blomqvist M, et al. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol 2009;39:1726-1735.
152. Girardi E, et al. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat Immunol 2012; doi:10.1038/ni.2371.
153. Patel O, et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol 2012; doi:10.1038/ni.2372.
154. Adams JJ, et al. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity 2011;35:681-693.